T Buclin

Summary

Affiliation: Centre Hospitalier Universitaire Vaudois
Country: Switzerland

Publications

  1. pmc Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients
    Eva Maria Staehli Hodel
    Swiss Tropical and Public Health Institute, University of Basel, Basel, Switzerland
    Malar J 12:235. 2013
  2. ncbi request reprint [Prescribing monitoring in clinical practice: from enlightened empiricism to rational strategies]
    Thierry Buclin
    Division de pharmacologie clinique, Département des laboratoires, Hôpital de Beaumont CHUV, 1011 Lausanne
    Rev Med Suisse 9:1037-41. 2013
  3. pmc Monitoring drug therapy
    Thierry Buclin
    Division of Clinical Pharmacology and Toxicology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    Br J Clin Pharmacol 73:917-23. 2012
  4. pmc Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients
    Nancy Perrottet
    Microbiology Institute, University Hospital, Lausanne, Switzerland
    BMC Infect Dis 10:2. 2010
  5. pmc Development and validation of decision rules to guide frequency of monitoring CD4 cell count in HIV-1 infection before starting antiretroviral therapy
    Thierry Buclin
    Division of Clinical Pharmacology and Toxicology, University Hospital Center and University of Lausanne, Lausanne, Switzerland
    PLoS ONE 6:e18578. 2011
  6. ncbi request reprint [Will good clinical practice domesticate human research?]
    T Buclin
    Division de pharmacologie et toxicologie cliniques, Hôpital de Beaumont CHUV, Lausanne
    Rev Med Suisse 2:992-6. 2006
  7. doi request reprint An ultra performance liquid chromatography-tandem MS assay for tamoxifen metabolites profiling in plasma: first evidence of 4'-hydroxylated metabolites in breast cancer patients
    E Dahmane
    Division of Clinical Pharmacology and Toxicology, Department of Medecine, Lausanne, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Switzerland
    J Chromatogr B Analyt Technol Biomed Life Sci 878:3402-14. 2010
  8. pmc High cefepime plasma concentrations and neurological toxicity in febrile neutropenic patients with mild impairment of renal function
    F Lamoth
    Infectious Diseases Service, Department of Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Rue du Bugnon 46, CH 1011 Lausanne, Switzerland
    Antimicrob Agents Chemother 54:4360-7. 2010
  9. ncbi request reprint Specific determination of PAH and its N-acetyl metabolite by HPLC increases the accuracy and precision of PAH clearance measurements
    L A Decosterd
    Departement de Medecine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    Ren Fail 20:311-7. 1998
  10. doi request reprint Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals
    M Arab-Alameddine
    Division of Clinical Pharmacology and Toxicology, University Hospital Center, University of Lausanne, Lausanne, Switzerland
    Clin Pharmacol Ther 85:485-94. 2009

Collaborators

Detail Information

Publications38

  1. pmc Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients
    Eva Maria Staehli Hodel
    Swiss Tropical and Public Health Institute, University of Basel, Basel, Switzerland
    Malar J 12:235. 2013
    ..This study investigated the pharmacokinetics of three different forms of artemisinin combination therapy (ACT) in Tanzania and Cambodia to quantify and identify potential sources of variability...
  2. ncbi request reprint [Prescribing monitoring in clinical practice: from enlightened empiricism to rational strategies]
    Thierry Buclin
    Division de pharmacologie clinique, Département des laboratoires, Hôpital de Beaumont CHUV, 1011 Lausanne
    Rev Med Suisse 9:1037-41. 2013
    ..A formal conceptualization of monitoring is being developed and should support the rational development of monitoring strategies and their validation through appropriate clinical trials...
  3. pmc Monitoring drug therapy
    Thierry Buclin
    Division of Clinical Pharmacology and Toxicology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    Br J Clin Pharmacol 73:917-23. 2012
    ....
  4. pmc Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients
    Nancy Perrottet
    Microbiology Institute, University Hospital, Lausanne, Switzerland
    BMC Infect Dis 10:2. 2010
    ..This prospective observational study aimed to correlate clinical and cytomegalovirus (CMV) viral load response (DNAemia) with ganciclovir plasma concentrations in patients treated with valganciclovir for CMV infection/disease...
  5. pmc Development and validation of decision rules to guide frequency of monitoring CD4 cell count in HIV-1 infection before starting antiretroviral therapy
    Thierry Buclin
    Division of Clinical Pharmacology and Toxicology, University Hospital Center and University of Lausanne, Lausanne, Switzerland
    PLoS ONE 6:e18578. 2011
    ..We developed rules to guide frequency of CD4 cell count monitoring in HIV infection before starting antiretroviral therapy, which we validated retrospectively in patients from the Swiss HIV Cohort Study...
  6. ncbi request reprint [Will good clinical practice domesticate human research?]
    T Buclin
    Division de pharmacologie et toxicologie cliniques, Hôpital de Beaumont CHUV, Lausanne
    Rev Med Suisse 2:992-6. 2006
    ..No clinical study should be planned without consideration of a series of legal requirements, which are reviewed. Concerns about their practical implications are critically assessed...
  7. doi request reprint An ultra performance liquid chromatography-tandem MS assay for tamoxifen metabolites profiling in plasma: first evidence of 4'-hydroxylated metabolites in breast cancer patients
    E Dahmane
    Division of Clinical Pharmacology and Toxicology, Department of Medecine, Lausanne, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Switzerland
    J Chromatogr B Analyt Technol Biomed Life Sci 878:3402-14. 2010
    ....
  8. pmc High cefepime plasma concentrations and neurological toxicity in febrile neutropenic patients with mild impairment of renal function
    F Lamoth
    Infectious Diseases Service, Department of Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Rue du Bugnon 46, CH 1011 Lausanne, Switzerland
    Antimicrob Agents Chemother 54:4360-7. 2010
    ..Careful adherence to normalized dosing per 100 ml/min GFR is crucial. Monitoring of plasma concentrations may contribute to preventing neurological toxicity of high-dose therapy for this life-threatening condition...
  9. ncbi request reprint Specific determination of PAH and its N-acetyl metabolite by HPLC increases the accuracy and precision of PAH clearance measurements
    L A Decosterd
    Departement de Medecine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    Ren Fail 20:311-7. 1998
    ..87 +/- 0.13 implying unphysio-logical values (> 1) in some cases. In conclusion HPLC not only enables the simultaneous quantitation of PAH and NAc-PAH, but may also provide more accurate and precise PAH clearance measurements...
  10. doi request reprint Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals
    M Arab-Alameddine
    Division of Clinical Pharmacology and Toxicology, University Hospital Center, University of Lausanne, Lausanne, Switzerland
    Clin Pharmacol Ther 85:485-94. 2009
    ..Therefore, dosage adjustment in accordance with the type of polymorphism (CYP2B6, CYP2A6, or CYP3A4) is required in order to maintain EFV within the therapeutic target levels...
  11. ncbi request reprint Estimation of glomerular filtration rate by sinistrin clearance using various approaches
    T Buclin
    Division of Clinical Pharmacology, University Hospital, Lausanne, Switzerland
    Ren Fail 20:267-76. 1998
    ..D/AUC represents the most advisable approach for snapshot renal testing in subjects or patients without important renal impairment...
  12. ncbi request reprint [Effects of oral cannabis and dronabinol on driving capacity]
    C Giroud
    Laboratoire de toxicologie et chimie forensiques, institut universitaire de médecine légale IUML, Rue du Bugnon 21, CH 1005 Lausanne, Suisse
    Ann Pharm Fr 64:161-72. 2006
    ..The Cannabis Influence Factor (CIF) which relies on the molar ratio of active and inactive cannabinoids in blood provided a good estimate of the fitness to drive...
  13. ncbi request reprint [Risk of overtreatment: not to be neglected. The example of antiepileptic drugs]
    L E Rothuizen
    Division de pharmacologie et toxicologie cliniques, Département de médecine Hôpital Beaumont, CHUV, Lausanne
    Rev Med Suisse 2:976-80. 2006
    ..Its prevention requires the recognition of the situations and the understanding of the mechanisms leading to it. The pharmacological treatment of epilepsy exposes to such a risk and serves as an example for its detection and correction...
  14. ncbi request reprint [Trends in drug therapy]
    F Livio
    Division de pharmacologie et toxicologie cliniques, Departement de Medecine, CHUV, Lausanne
    Rev Med Suisse 2:155-9. 2006
    ..Risk-benefit assessment of drugs is a dynamic process. One must keep in mind that the data on the relationship between drugs and the clinical picture are of variable quality and that the size of the risk is often difficult to assess...
  15. ncbi request reprint [Antimicrobial agents and renal elimination: towards individual dosage adjustment?]
    C Willi-Robatel
    Division de pharmacologie et toxicologie cliniques, Département des laboratoires, CHUV, Lausanne
    Rev Med Suisse 8:894-900. 2012
    ..The literature has been reviewed and compared to a predictive model of the fraction of drug cleared by the kidney based on the Dettli's principle. Revised drug dosing recommendations integrating these predictive parameters are proposed...
  16. ncbi request reprint [Pharmacovigilance update]
    F Livio
    Division de pharmacologie et toxicologie cliniques, Departement de Medecine, CHUV, 1011 Lausanne
    Rev Med Suisse 7:71-4. 2011
    ..The correct use of transdermal patches is reviewed with the example of rivastigmine. Aseptic meningitis is a rare adverse reaction of lamotrigine. An increased risk of fractures after long term use of proton pump inhibitors is suspected...
  17. ncbi request reprint [Pharmacovigilance]
    F Livio
    Division de pharmacologie et toxicologie cliniques, Département de médecine CHUV, 1011 Lausanne
    Rev Med Suisse 8:116-9. 2012
    ..Topiramate: Evidence of teratogenicity (oral clefts). Valproate: Impaired cognitive development in addition to well-known teratogenicity. Antipsychotics in late pregnancy: A risk of neonatal complications...
  18. ncbi request reprint [Pharmacovigilance update]
    F Livio
    Division de pharmacologie et toxicologie cliniques, Département de médecine CHUV, 1011 Lausanne
    Rev Med Suisse 6:128-31. 2010
    ..Raised concerns of causality between insuline glargine and malignant tumors are not supported by strong evidence. Proton pump inhibitors seem to blunt clopidogrel benefit. Aliskiren can cause angioedema...
  19. ncbi request reprint Population pharmacokinetics of fluconazole given for secondary prevention of oropharyngeal candidiasis in HIV-positive patients
    C Csajka
    Division of Clinical Pharmacology, University Hospital, CHUV, Lausanne, Switzerland
    Eur J Clin Pharmacol 57:723-7. 2001
    ....
  20. pmc Population pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovir
    N Perrottet
    Division of Clinical Pharmacology and Toxicology Département de Médecine, Hôpital de Beaumont 06, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    Antimicrob Agents Chemother 53:3017-23. 2009
    ..However, GCV plasma measurement may still be helpful in specific clinical situations...
  21. ncbi request reprint Inhibition of CYP2E1 by chlormethiazole as measured by chlorzoxazone pharmacokinetics in patients with alcoholism and in healthy volunteers
    C B Eap
    Departement universitaire de psychiatrie adulte, Hôpital de Cery, Prilly, Lausanne, Switzerland
    Clin Pharmacol Ther 64:52-7. 1998
    ..It is known that CYP2E1 is involved in the activation of many low-molecular-weight toxins and carcinogens and may be involved in the development of alcohol-induced liver disease...
  22. pmc Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein
    N Widmer
    Division of Clinical Pharmacology, University Hospital, Lausanne, Switzerland
    Br J Clin Pharmacol 62:97-112. 2006
    ....
  23. ncbi request reprint [Drugs and breastfeeding: some facts to consider before deciding they are incompatible]
    A Panchaud
    Division de pharmacologie et toxicologie cliniques, CHUV, Lausanne
    Rev Med Suisse 4:540-5. 2008
    ..This article aims to review the facts needed to assess amount of drug exposure to the child and to list the few drugs associated with significant effects on the nursing infant...
  24. pmc Reassessment of recommended imipenem doses in febrile neutropenic patients with hematological malignancies
    F Lamoth
    Department of Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Switzerland
    Antimicrob Agents Chemother 53:785-7. 2009
    ..The recommended 2-g/day regimen achieved coverage of the most common bacteria (MIC(90) = 1 mg/liter) during the whole dosing interval in only 53% of patients. This goal was achieved in 90% of patients with 3 g/day...
  25. ncbi request reprint Diet acids and alkalis influence calcium retention in bone
    T Buclin
    Division of Clinical Pharmacology, University Hospital CHUV, Lausanne, Switzerland
    Osteoporos Int 12:493-9. 2001
    ..Further studies are needed to determine the clinical impact of dietary counseling for avoiding diet acids as a preventive measure against osteoporosis...
  26. ncbi request reprint [Antiepileptics in women of childbearing age and during pregnancy : Comparison of specialized information with the current state of knowledge in Germany and Switzerland]
    U Winterfeld
    Division de pharmacologie clinique, Swiss Teratogen Information Service, Centre hospitalier universitaire vaudois CHUV et Université de Lausanne, Rue du Bugnon 17 01 104, 1011, Lausanne, Schweiz
    Nervenarzt 85:738-46. 2014
    ..The aim of this article is to present an overview of the teratogenic potential of various antiepileptic drugs and to compare these data with the information provided by the SmPCs...
  27. ncbi request reprint [Pharmacovigilance update]
    F Livio
    Division de pharmacologie et toxicologie cliniques, CHUV, 1011 Lausanne
    Rev Med Suisse 4:150-4. 2008
    ..Besides biological investigations of questionable relevance and clinical trial of inconstant efficiency towards safety outcomes, the role of pharmacovigilance notifications by practitioners remains of paramount importance...
  28. ncbi request reprint [Serotonin syndrome: review and case series from the Swiss pharmacovigilance system]
    M Chassot
    Division de pharmacologie et toxicologie cliniques, Departement de Medecine, Hôpital de Beaumont, CHUV, 1011 Lausanne
    Rev Med Suisse 8:2086-90. 2012
    ..We also analyzed the 102 cases notified to Swissmedic from 1998 to 2009, focusing on patients profile and suspected drugs...
  29. doi request reprint A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: Raltegravir, maraviroc, darunavir, and etravirine
    A Fayet
    Division of Clinical Pharmacology and Toxicology, University Hospital of Lausanne, Switzerland
    J Chromatogr B Analyt Technol Biomed Life Sci 877:1057-69. 2009
    ....
  30. pmc Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability
    N Widmer
    Division of Clinical Pharmacology, Department of Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    Br J Cancer 98:1633-40. 2008
    ..Our findings represent additional arguments to further evaluate the usefulness of individualizing imatinib prescription based on a therapeutic drug monitoring programme, possibly associated with target genotype profiling of patients...
  31. ncbi request reprint Characterization of a selective antagonist of neuropeptide Y at the Y2 receptor. Synthesis and pharmacological evaluation of a Y2 antagonist
    E Grouzmann
    Division d Hypertension, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    J Biol Chem 272:7699-706. 1997
    ..48. Thus, to our best knowledge, T4-[NPY(33-36)]4 represents the first potent and selective Y2 antagonist...
  32. ncbi request reprint Disposition of voriconazole during continuous veno-venous haemodiafiltration (CVVHDF) in a single patient
    C Robatel
    Division of Clinical Pharmacology and Toxicology, Department of Medicine, University Hospital, Lausanne, Switzerland
    J Antimicrob Chemother 54:269-70. 2004
    ..To determine whether voriconazole dosage adjustment is required during continuous veno-venous haemodiafiltration (CVVHDF)...
  33. ncbi request reprint Pharmacokinetics and dosage adaptation of meropenem during continuous venovenous hemodiafiltration in critically ill patients
    C Robatel
    Division of Clinical Pharmacology, Department of Medicine, University Hospital, Lausanne, Switzerland
    J Clin Pharmacol 43:1329-40. 2003
    ..The results indicate that two different therapeutic schedules of meropenem are equally applicable to patients receiving CVVHD: either 750 mg tid or 1500 bid...
  34. ncbi request reprint Delta(9)-THC, 11-OH-Delta(9)-THC and Delta(9)-THCCOOH plasma or serum to whole blood concentrations distribution ratios in blood samples taken from living and dead people
    C Giroud
    Laboratoire de Toxicologie Analytique, , Lausanne, Switzerland
    Forensic Sci Int 123:159-64. 2001
    ..6 to calculate plasma concentrations from blood values. In the case of blood samples taken after death, the use of these models to assess the time of Cannabis use is not recommended...
  35. ncbi request reprint The effects of morphine on dyspnea and ventilatory function in elderly patients with advanced cancer: a randomized double-blind controlled trial
    C Mazzocato
    Division of Palliative Care, University Hospital, Lausanne, Switzerland
    Ann Oncol 10:1511-4. 1999
    ..This study was undertaken to assess the efficacy of morphine on dyspnea and its safety for ventilatory function in elderly advanced cancer patients...
  36. ncbi request reprint Determination of imatinib (Gleevec) in human plasma by solid-phase extraction-liquid chromatography-ultraviolet absorbance detection
    N Widmer
    Division de pharmacologie clinique, Laboratoire BH 18 218, Departement de Medecine, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne CHUV, Switzerland
    J Chromatogr B Analyt Technol Biomed Life Sci 803:285-92. 2004
    ..7%). The method has been validated and is currently being applied in a clinical study assessing the imatinib plasma concentration variability in a population of chronic myeloid leukemia- and gastro-intestinal stromal tumor-patients...
  37. ncbi request reprint Resistance reversal by RNAi silencing of MDR1 in CML cells associated with increase in imatinib intracellular levels
    N Widmer
    Leukemia 21:1561-2; author reply 1562-4. 2007
  38. ncbi request reprint Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients
    C Marzolini
    Department of Medicine, University Hospital of Lausanne, Switzerland
    AIDS 15:71-5. 2001
    ..The important inter-individual variability in efavirenz levels strongly argues for dose adjustment on the basis of therapeutic drug monitoring to optimize treatment...